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Current guidelines for air sampling for bacteria and fungi in compounding pharmacies require the use of a medium for each
type of organism. U.S. Pharmacopeia (USP) chapter<797> (http://www.pbm.va.gov/linksotherresources/docs/USP797
PharmaceuticalCompoundingSterileCompounding.pdf) calls for tryptic soy agar with polysorbate and lecithin (TSApl) for bac-
teria andmalt extract agar (MEA) for fungi. In contrast, the Controlled Environment Testing Association (CETA), the profes-
sional organization for individuals who certify hoods and clean rooms, states in its 2012 certification application guide (http:
//www.cetainternational.org/reference/CAG-009v3.pdf?sid1267) that a single-plate method is acceptable, implying that it is
not always necessary to use an additional medium specifically for fungi. In this study, we reviewed 5.5 years of data from our lab-
oratory to determine the utility of TSApl versus yeast malt extract agar (YMEA) for the isolation of fungi. Our findings, from
2,073 air samples obtained from compounding pharmacies, demonstrated that the YMEA yielded>2.5 times more fungal iso-
lates than TSApl.
Compounded sterile preparations (CSPs) are pharmaceuticalpreparations that must be carefully and aseptically admixed
by a licensed pharmacist or pharmacy tech in a specially designed
and designated clean-roomenvironment. This preparation is then
administered to a patient, often by an intravenous (i.v.), intrathe-
cal, or intraocular route (American Society of Health-System
Pharmacists U.S. Pharmacopeia [USP] chapter 797 discus-
sion guide for compounding sterile preparations, http://www
.ashp.org/s_ashp/docs/files/discguide797-2008.pdf). Contami-
nated CSPs, such as total parenteral nutrition (TPN) and
chemotherapy drugs made in hospital pharmacies and/or freestand-
ing compounding pharmacies, are a notable source of serious infec-
tions (1–16; see also theCDCreport of amultistate fungalmeningitis
outbreak [http://www.cdc.gov/hai/outbreaks/meningitis-map.html]
and the FDA report of an intravenous compounded products re-
call [http://www.fda.gov/Safety/MedWatch/SafetyInformation
/SafetyAlertsforHumanMedicalProducts/ucm249099.htm]). The
USP created chapter 797 to establish standardized protocols
to ensure the preparation of sterile and safe CSPs (17). A corner-
stone of chapter 797 is the verification that the pharmacy
clean-room environment is maintained free from significant
sources of contamination (18). One of the approaches used for
this process is air sampling to detect excessive bacterial and
fungal organisms in the clean-room environment. USP chapter
797 specifies that air sampling be conducted semiannually
at a minimum for both bacteria and fungi (see the American
Society of Health-System Pharmacists USP chapter797 dis-
cussion guide [http://www.ashp.org/s_ashp/docs/files/discguide797-
2008.pdf]).
It is important to note that U.S. sterile i.v. compounding phar-
macies operate under state licensing guidelines, and USP chapter
797 has not been universally adopted, so that actual practices
vary across the country. Certified registered clean-room profes-
sionals (Certifiers), through their trade association guidelines, the
Controlled Environment Testing Association (CETA) 2012 certi-
fication and application guide (see http://www.cetainternational
.org/reference/CAG-009v3.pdf?sid1267), describe two sam-
pling methods, a single-plate method and a duplicate-plate
method, thus implying that it is not always necessary to use an
additional medium specifically for fungi. In order to determine
whether bacterial and fungal media are both necessary, we did a
retrospective look back and examined data from a 5.5-year time
period of air sampling in 30 hospital pharmacies and two free-
standing sterile compounding pharmacies. The environmental
monitoring in these pharmacies was performed in the normal
course of business by Microbiology Specialists Incorporated
(MSI).
(R.A.J. presented a poster of this work at the Texas TechHealth
Sciences Center–Paul L. Foster School of Medicine in fulfillment
of a requirement to do clinical research in the Scholarly Activity
and Research Program.)
MATERIALS AND METHODS
Air sampling was performed using a volumetric air sampler (SAS 180;
Bioscience International, Rockville, MD). A bacterial medium (tryptic
soy agar [TSA] with polysorbate and lecithin [TSApl]) and a fungal
medium (yeast malt extract agar [YMEA]) were used. Both bacterial
and fungal media were prepared and packaged by Anaerobe Systems,
Morgan Hill, CA. Both media were packaged in sealed foil pouches
with sterile absorbent pads; this prevents the accumulation of mois-
ture (condensate) often seen with plates in cellophane sleeves when
they are transported. Per USP chapter 797 instructions, a prede-
Received 9 April 2013 Returned for modification 6 May 2013
Accepted 29 July 2013
Published ahead of print 31 July 2013
Address correspondence to Alice S. Weissfeld, alice@microbiologyspecialists.com.
Copyright © 2013, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JCM.00944-13
3172 jcm.asm.org Journal of Clinical Microbiology p. 3172–3175 October 2013 Volume 51 Number 10
 o
n
 Septem
ber 12, 2018 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
termined volume of air (between 400 and 1,000 liters) was collected
based on the size of the hoods, their location in the compounding
areas, and the positioning of supply and return vents in each sterile
compounding area.
One TSApl plate and one YMEA plate were collected at each loca-
tion. Plates were all returned to MSI for analysis. The TSApl plates
were incubated for 72 h at 35°C 2°C, and YMEA was incubated for 5
to 7 days at 28°C  2°C. A certified microbiologist then counted and
identified the colonies on each plate. Results were reported as the
number of CFU per cubic meter of air (CFU/m3). Any potential patho-
gens were noted. USP chapter 797 defines action limits for hoods,
i.v./buffer areas, and anterooms (where donning of personal protec-
tive equipment [PPE] occurs). In addition, the presence of a potential
pathogen in any sample is considered significant, indicates that the
area has failed to comply with action limits, and must be reported to
the pharmacy immediately.
RESULTS
A total of 2,073 environmental samples for monitoring (air
samples) were collected from compounding pharmacies and
examined at Microbiology Specialists Incorporated (MSI).
Table 1 shows the total number of air samples collected per
year and the number of sampling results that failed. Overall, in 5.5
years of testing, 34% of all air samples exceeded action limits or
contained potential pathogens.
Table 2 shows the number of air samples collected per year
and the number of sample results that contained potentially
pathogenic bacteria. Bacillus spp. were the most frequently iso-
lated bacterial contaminants. However, Gram-negative rods,
such as Enterobacteriaceae, Pseudomonas, Stenotrophomonas,
Acinetobacter, and even Mycobacterium and Nocardia spp.,
were recovered.
Table 3 shows the number of air samples collected per year and
the number of those sample results that contained potentially
pathogenic fungi. Aspergillus, Acremonium, and Fusarium were
the most frequently isolated molds, with a diverse group of other
molds and yeasts also recovered.
Table 4 shows the numbers of potentially pathogenic bacteria
and fungi side by side. Of note, during 4 of the 6 years, more
potentially pathogenic fungi were isolated than potentially patho-
genic bacteria.
Table 5 shows the total percentage of fungi that grew on YMEA
versus TSApl. In fact, over the 5.5-year period, 285/388 (73%) of
the fungi grew only on YMEA. The number of fungi that grew on
TSApl alone was 103/388 (27%).
DISCUSSION
In 2004, theU.S. Pharmacopeia (USP) published chapter797, in
which it outlined aprogram to ensure that sterile compoundedprep-
arations were indeed sterile when they reached the patient (17). The
chapter was revised in 2007 (see http://www.pbm.va.gov/linksotherr
esources/docs/USP797PharmaceuticalCompoundingSterileCompo
unding.pdf). From the microbiology perspective, the program in-
volves environmental monitoring in the i.v. pharmacy, as well as a
robust program to validate compounder competency (19). During
this time, there were already incidences of patient morbidity and
mortality from contaminated preparations, thus demonstrating a
need for such a program (3, 5, 6, 7, 10, 12, 13, 14, 15, 16). Using
microbial fingerprinting, we have previously shown that the same
Brevibacillus brevis found in theairof apharmacycleanroomwasalso
isolated from an i.v. bag prepared under the hood in the clean room
that same day (19).
Unfortunately, there is currently no mandatory accreditation
or inspection for pharmacies. Furthermore, many state boards of
pharmacy have not even adopted the chapter 797 rules. Per-
haps, as professionals and organizations who are involved with
CSP preparation see an environmental air sample test failure rate
similar to the ones described here, which average 33% per year
over the 5.5-year period analyzed, the compounders will embrace
a robust quality assurance program which will mitigate contami-
nation in the pharmacy.Our results indicate that this type ofmon-
itoring should include a specific fungal medium to reliably dem-
onstrate the presence of fungal contaminants, which may also be
human pathogens.
On 31 January 2012, the CETA published its certification
application guide detailing its position on USP chapter797
viable environmental sampling (http://www.cetainternational
.org/reference/CAG-009v3.pdf?sid1267). In it, CETA advo-
cates the use of a general microbiological medium such as tryp-
tic soy agar, its so-called single-plate method. CETA advocates
TABLE 1 Total numbers of samples and failed samples per year
Yr
Total no. of
samples
No. of failed
samples
% of failed
samples
2007 227 82 36
2008 306 81 26
2009 437 131 30
2010 563 204 36
2011 457 180 39
2012a 83 30 36
a Six months only.
TABLE 2 Samples with potentially pathogenic bacteria
Yr
Total no. of
samples
No. of
Bacillus spp.
No. of Gram-
negative rods
No. of aerobic
Actinomycetes No. of samples with other bacteria
2007 227 46 6
2008 306 33 4 3 (1 Serratia, 1 Pseudomonas, 1 Stenotrophomonas)
2009 437 78 25 9 16 (6 Pseudomonas, 3 Stenotrophomonas, 2Mycobacterium, 2 Sphingomonas,
1 Enterobacter, 1 Acinetobacter, 1 Brevundimonas)
2010 563 100 57 28 3 (Acinetobacter)
2011 457 79 33 31 4 (1 Sphingomonas, 3 Acinetobacter)
2012a 83 19 9 1
a Six months only.
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incubating these plates at 30°C to 35°C for 48 to 72 h and then
reincubating the same plates at 26°C to 30°C for 5 to 7 days.
What CETA is advocating does not match any published stan-
dard method for examination of bacteria or fungi that we know
of. In fact, USP chapter797 calls for TSA to be incubated at
30°C to 35°C for 48 to 72 h and malt extract agar or other
suitable fungal media to be incubated at 26°C to 30°C for 5 to 7
days.
Our data do not support the CETA approach. Ideally, a
study should be set up comparing the USP and CETAmethods.
However, we worry that lowering the temperature after incu-
bation at 35°C, as stated in the CETA guideline, would cause
the inhibition of fungal growth and inability to sporulate. Fur-
ther, having to perform additional subcultures because of in-
hibited or sterile growth would mean that getting information
to the i.v. compounding pharmacy would subsequently be de-
layed. We were able to do tape preparations or tease mounts to
identify the fungi directly from YMEA. The idea here is that the
use of fungal media when looking for fungi is a primary tenet of
microbiology. We question why hood and clean-room certifi-
ers are even discussing best practices for the microbiology
laboratory in the CETA document, especially when advocating
a method not even approved in USP chapter 797. In any
case, analysis of 5.5 years of data of 2,073 environmental air samples
has shown that two media (one bacterial and one fungal) must be
used in order to effectively track and correct any problems.
TABLE 3 Samples with potentially pathogenic fungi
Yr
Total no. of
samples
No. of samples with:
No. of samples with other fungiAspergillus Acremonium Fusarium Yeast
2007 227 19 2 7 3 14 (3 Aureobasidium, 2
Hormographiella, 4 Rhizopus,
3 Pithomyces, 1 Sporothrix, 1
Ochroconis)
2008 306 17 3 2 3 13 (1 Scopulariopsis, 3
Paecilomyces, 2
Aureobasidium, 6 Pithomyces,
1Microsporum)
2009 437 17 5 4 8 16 (1 Sporothrix, 3
Aureobasidium, 4
Scopulariopsis, 1
Tritarachium roseum, 1
Cunninghamella, 1
Verticillium, 4 Paecilomyces,
1 Rhizopus)
2010 563 34 13 13 30 17 (2 Geotrichum, 2
Paecilomyces, 2 Sporothrix, 1
Hormographiella, 1
Ochroconis, 3Microsporum, 1
Hyalodendron, 1 Beauveria, 1
Rhinocladiella, 3 Pithomyces)
2011 457 39 18 10 19 12 (1 Scopulariopsis, 1
Paecilomyces, 3Malbranchea,
1 Trichoderma, 4 Geotrichum,
1 Basipetospora rubra, 1
Zygomycetes)
2012a 83 1 0 0 7 1 (Aureobasidium)
a Six months only.
TABLE 4 Total percentages of potentially pathogenic bacteria and fungi
Yr
Potentially pathogenic
bacteria
Potentially pathogenic
fungi
Total
no.
% of failed
samples
Total
no.
% of failed
samples
2007 33 40 49 60
2008 36 44 45 56
2009 76 58 55 42
2010 89 44 115 56
2011 67 37 113 63
2012a 19 63 11 37
a Six months only.
TABLE 5 Total percentages of fungi on TSApl and YMEA
Yr
Total no. of
samples
Fungi on YMEA Fungi on TSApl
Total
no. %
Total
no. %
2007 49 39 80 10 20
2008 45 34 76 11 24
2009 55 39 71 16 29
2010 115 86 75 29 25
2011 113 79 70 34 30
2012a 11 8 73 3 27
Total 388 285 73 103 27
a Six months only.
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